Guggenheim Capital’s Revance Therapeutics, Inc. RVNC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-58,303
| Closed | -$177K | – | 1718 |
|
|
2024
Q4 | $177K | Sell |
58,303
-569
| -1% | -$1.73K | ﹤0.01% | 1609 |
|
|
2024
Q3 | $306K | Buy |
+58,872
| New | +$306K | ﹤0.01% | 1607 |
|
|
2022
Q4 | – | Sell |
-32,735
| Closed | -$884K | – | 2009 |
|
|
2022
Q3 | $884K | Sell |
32,735
-1,823
| -5% | -$49.2K | 0.01% | 1197 |
|
|
2022
Q2 | $478K | Sell |
34,558
-2,247
| -6% | -$31.1K | ﹤0.01% | 1600 |
|
|
2022
Q1 | $718K | Buy |
36,805
+1,043
| +3% | +$20.3K | ﹤0.01% | 1518 |
|
|
2021
Q4 | $583K | Buy |
35,762
+158
| +0.4% | +$2.58K | ﹤0.01% | 1613 |
|
|
2021
Q3 | $992K | Sell |
35,604
-827
| -2% | -$23K | 0.01% | 1417 |
|
|
2021
Q2 | $1.08M | Buy |
36,431
+1,667
| +5% | +$49.4K | 0.01% | 1447 |
|
|
2021
Q1 | $972K | Buy |
34,764
+16,578
| +91% | +$464K | 0.01% | 1411 |
|
|
2020
Q4 | $515K | Buy |
+18,186
| New | +$515K | ﹤0.01% | 1627 |
|